Nasdaq

Sionna Therapeutics Presents Preclinical Data on Novel CFTR Modulators at the 48th European Cystic Fibrosis Conference

Sionna Therapeutics, Inc. has announced the presentation of promising preclinical data at the 48th European Cystic Fibrosis Conference in Milan, showing that its nucleotide-binding domain 1 (NBD1) ...
Healio

Underrepresented groups with cystic fibrosis less likely to be eligible for CFTR modulators

Please provide your email address to receive an email when new articles are posted on . Patients from minority racial and ethnic groups with cystic fibrosis are less likely to be eligible for cystic ...
Healio

Cystic fibrosis triple therapy outcomes improve regardless of prior modulators

Please provide your email address to receive an email when new articles are posted on . Triple therapy improved lung function, BMI and other factors. Patients naïve to cystic fibrosis transmembrane ...
Cystic Fibrosis Foundation

Giving Voice to Those Without Modulators

For those who don’t benefit from modulators, the fight against CF can feel isolating and uncertain. Five members of our community share how they’ve transformed their personal struggles into purpose — ...

Sionna Therapeutics to Participate in Upcoming December Investor Conferences

Live webcasts of the presentations will be available under the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. Replays will also be available ...
Yahoo Finance

ERS 2025: Long-term CFTR use shows clinical benefit but variable microbial impact

At the 2025 European Respiratory Society (ERS) International Congress taking place in Amsterdam, the Netherlands, from 27 September to 1 October, researchers from Canada's Dalhousie University and the ...
Seeking Alpha

Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

- ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene ...
Business Wire

Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference

-Interim results of largest real-world study of TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) showed sustained improvement in lung function, reduction ...
Pulmonology Advisor

ETI May Improve Bronchial Dilatations in Adolescents With Cystic Fibrosis

Elexacaftor-tezacaftor-ivacaftor (ETI) may improve bronchial dilatations in adolescents with cystic fibrosis (CF).
News Medical

CFTR modulator can be safe, well-tolerated for younger children with common form of cystic fibrosis

Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently.
Nasdaq

Sionna Therapeutics to Present Preclinical Data on CFTR Modulators at European Cystic Fibrosis Conference

Sionna Therapeutics, Inc. announced that preclinical data on its novel cystic fibrosis (CF) treatment candidates, SION-451 and SION-719, will be presented at the European Cystic Fibrosis Society’s ...